Current treatment of HER 2+ metastatic breast cancer
- PMID: 28981328
- DOI: 10.12968/bjon.2017.26.Sup16a.S7
Current treatment of HER 2+ metastatic breast cancer
Abstract
Historically, HER2-positive breast cancer had a poor prognosis. The development of molecul ar ther apies that target the HER2 receptor has TR ansformed outcomes. Here, the evidence on Anti-HER2 therapies is summarised.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous